Aehr Test Systems (AEHR) has had the highest return this year by a mid-cap US stock, returning 405.2%.
| ASSET | YEAR | % RETURN |
|---|---|---|
Aehr Test Systems (AEHR) | 2026 | 405.23% |
Erasca (ERAS) | 2026 | 388.41% |
AXT (AXTI) | 2026 | 329.13% |
Twist Bioscience (TWST) | 2026 | 293.57% |
MaxLinear (MXL) | 2026 | 283.85% |
Enliven Therapeutics (ELVN) | 2026 | 283.35% |
Maase (MAAS) | 2026 | 283.33% |
Immunitybio (IBRX) | 2026 | 270.79% |
P3 Health Partners (PIII) | 2026 | 262.43% |
10X Genomics (TXG) | 2026 | 259.1% |
Oruka Therapeutics (ORKA) | 2026 | 246.88% |
Ichor (ICHR) | 2026 | 237.52% |
Definium Therapeutics (DFTX) | 2026 | 234.44% |
Veradermics (MANE) | 2026 | 225.74% |
Spyre Therapeutics (SYRE) | 2026 | 221.52% |
Ultra Clean (UCTT) | 2026 | 214.73% |
Tango Therapeutics (TNGX) | 2026 | 212.66% |
Pulse Biosciences (PLSE) | 2026 | 200.14% |
Iridium Communications (IRDM) | 2026 | 184.12% |
Alumis (ALMS) | 2026 | 181.78% |
Penguin Solutions (PENG) | 2026 | 177.57% |
Hemab Therapeutics Holdings, Inc Common Stock (COAG) | 2026 | 177.06% |
Abcellera Biologics (ABCL) | 2026 | 173.1% |
Dianthus Therapeutics (DNTH) | 2026 | 171.95% |
Liquidia Technologies (LQDA) | 2026 | 163.55% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.